What's next in tech
Map Pharmaceuticals of Mountain View said today it has suspended development of its drug candidate aimed at asthma in children after its development partner, AstraZeneca terminated its license agreement Read More → 
Maxygen, the Redwood City biotech company that hired Lazard last October to help it explore "strategic options" about the same time it laid off 30 percent of its staff, Read More → 
Shares of Palo Alto's Jazz Pharmaceuticals rose by more than a third in after hours trading Wednesday after the company reported positive results from the second of its Phase Read More → 
Facet Biotech of Redwood City notified the SEC Tuesday that one of its shareholders, Roderick Wong, who controls some 124,828 shares, plans to offer five of his own nominees Read More → 
NeurogesX said Thursday that the European Medicines Agency's committee for medicinal products for human use has recommended approval of Qutenza, the San Mateo biopharmaceutical's treatment of peripheral neuropathic pain Read More → 
CV Therapeutics, the Palo Alto biopharmaceutical company fending off unsolicited overtures from Japan's second largest drug company, reported today that its new oral compound CVT-3619, designed to treat cardiometabolic Read More → 
